Use of High-Efficacy Therapies for Treatment of Relapsing Multiple Sclerosis

Lawrence Steinman, MD discusses the role of MRI and the McDonald Criteria for the diagnosis of multiple sclerosis, and Enrique Alvarez, MD, PhD defines key differences in the presentation and prevalence of its clinical subtypes.

Experts in the management of relapsing/remitting multiple sclerosis provide key insights on the importance of early diagnosis and treatment as well as what factors to consider when selecting therapy.

Key opinion leaders in neurology, Lawrence Steinman, MD and Enrique Alvarez, MD, PhD examine some advantages associated with beginning patients on higher-efficacy therapies for relapsing/remitting multiple sclerosis.

Two experts in multiple sclerosis share insights on the shared decision-making process when selecting a high efficacy therapy and emphasize the importance of disease characteristics and patient preference.

Enrique Alvarez, MD, PhD reviews factors to consider when monitoring response to treatment, and Lawrence Steinman, MD comments on patient- and disease-related factors that may impact therapeutic sequencing.

Experts in the management of multiple sclerosis provide key insights into the use of ublituximab in multiple sclerosis and review results of the ULTIMATE I and II trials from the AAN 2021 Annual Meeting.  

Thought leaders in neurology consider the role of BTK inhibitors such as evobrutinib and review the potential impact on patients with progressive multiple sclerosis.

Key opinion leaders in neurology, Lawrence Steinman, MD and Enrique Alvarez, MD, PhD, reflect on future developments in the management of multiple sclerosis and share key advice for community physicians.